However, because blockade of TIGIT can also promote T-cell activity [71], it is imperative to optimize the clinical setting to prevent severe GVHD and intensify the GVL effect in AML patients undergoing allo-HSCT. The gene discussed is TIGIT; the disease is acute myeloid leukemia.